130 related articles for article (PubMed ID: 22180399)
1. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
Rustin GJ
Ann Oncol; 2011 Dec; 22 Suppl 8():viii45-viii48. PubMed ID: 22180399
[TBL] [Abstract][Full Text] [Related]
2. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
Pignata S; Cannella L; Leopardo D; Bruni GS; Facchini G; Pisano C
Ann Oncol; 2011 Dec; 22 Suppl 8():viii40-viii44. PubMed ID: 22180398
[TBL] [Abstract][Full Text] [Related]
3. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Rustin GJ; van der Burg ME; Griffin CL; Guthrie D; Lamont A; Jayson GC; Kristensen G; Mediola C; Coens C; Qian W; Parmar MK; Swart AM; ;
Lancet; 2010 Oct; 376(9747):1155-63. PubMed ID: 20888993
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
Pelissier A; Bonneau C; Chéreau E; DE LA Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Anticancer Res; 2016 Apr; 36(4):1865-71. PubMed ID: 27069172
[TBL] [Abstract][Full Text] [Related]
5. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
6. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
8. Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.
Krell D; Said Battistino F; Benafif S; Ganegoda L; Hall M; Rustin GJS
Int J Gynecol Cancer; 2017 Jul; 27(6):1118-1122. PubMed ID: 28333841
[TBL] [Abstract][Full Text] [Related]
9. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.
Clarke T; Galaal K; Bryant A; Naik R
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006119. PubMed ID: 25198378
[TBL] [Abstract][Full Text] [Related]
11. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
12. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].
Vignot S; Brochet C; Debord C; Lauratet B; Bernard M
Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
14. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
15. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
16. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
[TBL] [Abstract][Full Text] [Related]
17. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
18. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
19. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
Pearl ML; Dong H; Tulley S; Zhao Q; Golightly M; Zucker S; Chen WT
Gynecol Oncol; 2015 May; 137(2):229-38. PubMed ID: 25769657
[TBL] [Abstract][Full Text] [Related]
20. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
